Clopidogrel Outperforms Aspirin in Preventing Heart Attacks & Strokes, Landmark Study Reveals
Madrid, Spain - In a potential paradigm shift for cardiovascular health, a major new study presented at the European Society of Cardiology congress in Madrid reveals that the commonly prescribed blood thinner clopidogrel is more effective than aspirin in preventing heart attacks and strokes – without increasing the risk of major bleeding. The findings, simultaneously published in The Lancet, could lead to widespread changes in treatment guidelines for the hundreds of millions globally living wiht coronary artery disease (CAD).
For decades, low-dose aspirin has been a cornerstone of preventative cardiology, recommended to reduce the “stickiness” of blood and lower the risk of serious cardiovascular events.Though, this new research challenges that long-held practice.
An international team of researchers, spanning the US, UK, australia, Switzerland, and Japan, conducted a complete analysis of nearly 29,000 patients with CAD. Their analysis of seven clinical trials demonstrated that patients taking clopidogrel experienced a 14% lower risk of major adverse cardiovascular or cerebrovascular events – encompassing heart attack, stroke, and cardiovascular death - compared to those on aspirin.
“This comprehensive synthesis of available evidence indicates that, in patients with CAD, long-term clopidogrel monotherapy offers superior protection against major cardiovascular and cerebrovascular events compared with aspirin, without an excess risk of bleeding,” the study authors wrote in The Lancet.
Understanding Coronary Artery Disease
CAD, the most common form of heart disease, affects over 300 million people worldwide, including 2.3 million in the UK. It develops when arteries supplying the heart become narrowed due to a buildup of atheroma, a fatty substance. This narrowing can cause angina (chest pain) and,if fully blocked,lead to a heart attack. Lifelong treatment is frequently enough necessary to prevent further complications.
Why This Matters
The study’s importance lies in its robust methodology and clear findings. Previous evidence supporting aspirin’s long-term benefits has been limited, and concerns about bleeding risks with alternative blood thinners have lingered.This research directly addresses those concerns, demonstrating comparable bleeding rates between clopidogrel and aspirin.
The researchers emphasize that these results should prompt “extensive adoption” of clopidogrel in clinical practice. While further discussion and guideline updates are expected, this discovery represents a meaningful advancement in the fight against heart disease, offering a possibly more effective preventative strategy for a vast patient population.
Learn More:
The lancet Study: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01562-4/fulltext01562-4/fulltext)
Related: Weight loss drugs can halve heart patients’ risk of early death, study finds: [https://www.theguardian.com/society/2025/aug/31
